ENTA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of -49.65%. Enanta Pharmaceuticals's return on equity of -70.18% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 167.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 47.26%. Given that Enanta Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Enanta Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.692, which suggesting that the stock is 30.793% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Enanta Pharmaceuticals's net income of -$22.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.80x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -70.18% beat Palatin Technologies's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 167.07%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3489.74%. Given that Palatin Technologies has higher upside potential than Enanta Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.692, which suggesting that the stock is 30.793% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than Palatin Technologies quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.3M is higher than Palatin Technologies's net income of --. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.80x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of -3965.99%. Enanta Pharmaceuticals's return on equity of -70.18% beat Recursion Pharmaceuticals's return on equity of -77.06%.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 167.07%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $8.71 which suggests that it could grow by 56.17%. Given that Enanta Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe Enanta Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.692, which suggesting that the stock is 30.793% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than Recursion Pharmaceuticals quarterly revenues of $4.5M. Enanta Pharmaceuticals's net income of -$22.3M is higher than Recursion Pharmaceuticals's net income of -$178.9M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.80x versus 26.17x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -70.18% beat Theriva Biologics's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 167.07%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 319.58%. Given that Theriva Biologics has higher upside potential than Enanta Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.692, which suggesting that the stock is 30.793% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than Theriva Biologics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.3M is lower than Theriva Biologics's net income of -$4.4M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.80x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.